Effectiveness of evidence-based medicine on knowledge, attitudes, and practices of family planning providers: a randomized experiment in Jordan by unknown
RESEARCH ARTICLE Open Access
Effectiveness of evidence-based medicine on
knowledge, attitudes, and practices of family
planning providers: a randomized experiment
in Jordan
Marianne El-Khoury1*, Rebecca Thornton2, Minki Chatterji3 and Soon Kyu Choi4
Abstract
Background: Provider misconceptions and biases about contraceptive methods are major barriers to family
planning access for women in low- and middle-income countries, including Jordan. Evidence-Based Medicine
(EBM) programs aim to reduce biases and misconceptions by providing doctors with the most up-to-date scientific
evidence on contraceptive methods.
Methods: We evaluate the effects of an EBM program conducted in Jordan on private providers’ knowledge,
attitudes, and practices. Family planning providers randomly assigned to a treatment group were invited to
attend a roundtable seminar on the injectable contraceptive Depot Medroxy Progesterone Acetate (DMPA),
and to receive two 15 min one-on-one educational visits that reinforce the messages from the seminar.
Results: There was low compliance with the EBM program. The study fails to detect an impact on providers’
knowledge of DMPA’s side effects or on reported clinical practices. There is suggestive evidence of a positive
impact on providers’ attitudes toward and confidence in prescribing the contraceptive to their patients. There is
also evidence of positive selection into program participation.
Conclusions: We conclude that EBM may not be effective as a stand-alone program targeting a family planning
method with a high level of provider and consumer bias. Evidence of positive selection into program participation
underscores the importance of randomization to avoid overestimating the true effects of interventions.
Trial registration: AEA RCT Registry, AEARCTR0000539, 11/3/2014
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Background
Provider misconceptions and biases about contraceptive
methods are major barriers to family planning access for
women in low- and middle-income countries [1]. Studies
in Tanzania, [2] Ghana, [3] and Bangladesh [4] have
demonstrated that family planning providers sometimes
deny women access to a particular contraceptive method
based on their own lack of knowledge and/or biases.
One approach to reduce biases and misconceptions is to
provide doctors with the most up-to-date scientific evi-
dence regarding contraceptive methods. This principle is
at the core of Evidence-Based Medicine (EBM). The
underlying assumption is that providers will use (and
share) the evidence-based information with their pa-
tients, rather than rely on their existing beliefs regarding
a particular method. This paper evaluates a program in
Jordan that provided private family planning doctors
with scientific evidence about Depot Medroxy Progester-
one Acetate (DMPA), a hormonal injectable contracep-
tive with low rates of use in Jordan.
EBM has been defined as the “conscientious, explicit
and judicious use of current best evidence in making
decisions about the care of individual patients” [5]. The
practice of EBM encourages health providers to con-
tinuously reference updated medical information and
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knowledge available through pre-appraised resources.
By combining this external evidence with their indi-
vidual clinical expertise and with patient preferences,
providers are enabled to deliver high quality health
services [6]. During the past decade the approach has
been used with private family planning providers in
Russia, [7] Armenia, [7] Bangladesh, [4] Egypt, [8]
Pakistan, [8] India, [8] the Philippines, [8] and Jordan
[9]. The hypothesized theory of change underlying this
approach is that EBM improves knowledge of family plan-
ning methods by providing credible documented evidence,
knowledge that in turn modifies existing negative attitudes
and practices among health providers.
However, to our knowledge, EBM programs in low-
and middle-income countries have not been rigorously
evaluated. One pre-post evaluation of an EBM program,
designed to provide evidence on Combined Oral Contra-
ception (COC) pills to Jordanian doctors, found that the
program increased providers’ knowledge about COC
pills, their willingness to prescribe COC pills to appro-
priate patients, and the reported number of times they
discussed family planning with their patients [9]. Else-
where, however, experimental evaluations of EBM pro-
grams related to other interventions, such as cancer,
smoking cessation, heart conditions, and pain manage-
ment (all conducted in the United States), have shown
mixed results [10–13].
Jordan is an appropriate setting to study the effective-
ness of EBM on provider knowledge, attitudes, and
practices related to family planning methods. It is a
middle-income country seeking to contain its rapidly
growing population, [14] yet with stagnant rates of use
of modern family planning methods, partly due to perva-
sive provider and consumer biases and misconceptions
towards these methods [15–19]. In particular, injectable
contraceptives, such as DMPA, are one of the least
popular contraceptive methods in the country among
providers and consumers alike [18, 20]. DMPA is not a
new method in Jordan and, to our knowledge, there are
no market shortages or health systems constraints that
explain the limited use of the contraceptive. We use an
experimental study design to evaluate an EBM program
in Jordan that aimed to reduce biases and misconcep-
tions towards DMPA.
We find no significant evidence that the EBM program
affected providers’ knowledge of the contraceptive’s side
effects or reported clinical practices, though we find sug-
gestive evidence of a positive impact on providers’ atti-
tudes toward, and self-reported confidence in, discussing
or prescribing DMPA. Given the low levels of demand of
DMPA, and concerns about its side effects more gener-
ally among Jordanian women, providers may be resistant
to adjusting their own attitudes and clinical practices,
especially because the EBM approach also encourages
them to take into account their patients’ preferences.
We find lower rates of participation in the EBM DMPA
program than prior EBM programs conducted on other
contraceptive methods in Jordan. Moreover, evidence of
positive selection suggests that these types of programs
may not attract providers who would benefit the most
from the information provided.
Methods
Sample
As part of a five-year program (2005–2010), the USAID-
funded Private Sector Project for Women’s Health began
working with private obstetricians/gynecologists and gen-
eral practitioners who provide family planning services in
Jordan, engaging them in multiple training programs, in-
cluding EBM programs on COC and Progesterone Only
Pills (POP). The EBM programs were implemented in four
regions of the country: Amman, Zarqa, the South, and the
North. The initial list, of 306 doctors, comprises (to the
best of our knowledge) all the private obstetricians/gyne-
cologists and general practitioners who provided family
planning services in Jordan in 2011. For this evaluation,
however, we chose to exclude doctors practicing in the
North and South regions of Jordan, because it was logis-
tically difficult to randomize them and to provide the
treatment to a widely dispersed group. Thus we removed
23 doctors working in the North region and 15 doctors
from the South region. We also excluded from the sample
one doctor who had participated in the development of
the EBM material. Our final sample consists of 267 private
doctors who provide services in Amman and Zarqa. (See
Additional file 1: CONSORT Flow Diagram.)
Study design
Using computer generated random numbers, we ran-
domly assigned doctors to treatment and control groups,
stratifying by geographic area and gender. Of our sample
of 267 private providers, 135 were randomly placed in
the treatment group and 132 in the control group. Due
to the stratification, the final numbers are uneven between
treatment and control groups. Random assignment was
conducted in 2011 prior to data collection. Participants
were not informed of their treatment assignment.
Ethics statement
Research was performed in accordance with the Declar-
ation of Helsinki. The study received exemption from
the Abt Associates Institutional Review Board (Reference
number: 0600). All interviewees were asked to provide
verbal consent before participating in the study and were
free to decline to participate. The study posed no more
than minimal risk to participants.
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Availability of supporting data
The data set supporting the results of this article are
available in the Inter-university Consortium for Political
and Social Research repository, http://doi.org/10.3886/
E19693V1 [21]. The study protocol is available from the
corresponding author, upon request.
The EBM DMPA program
Program staff invited the treatment group doctors to at-
tend a DMPA roundtable seminar and offered two edu-
cational visits that would reinforce the messages from
the seminar. The DMPA roundtable seminar consisted
of a two-hour session led by trained private peer pro-
viders who presented clinical research findings related to
DMPA. The roundtable format of the seminar allowed
providers to discuss these findings within the local con-
text, with the overall goal of correcting misconceptions
and biases and improving providers’ knowledge of
evidence-based health benefits of method use. The sem-
inar covered findings on return to fertility, anemia,
amenorrhea, and other real or perceived side effects of
DMPA. The two educational visits, to be scheduled
ahead of time with individual doctors, were conducted
by a trained health worker. These 15-minute one-on-one
sessions, held in individual providers’ clinics, were intended
to review specific information that was discussed during
the seminar. These sessions had three objectives: to en-
hance the availability of evidence to support providers in
counseling about DMPA; to address concerns about its side
effects and perceived harm (such as delays in returns to
fertility); and to convey information about its potential ben-
efits (such as protective effects against cancer). The seminar
and educational visits were implemented between January
and June 2012.
The control group providers were not invited to a DMPA
seminar and were not offered educational visits related to
DMPA. However, in order to continue to engage the con-
trol group providers during the period of the study (the first
six months of 2012), they were offered two repeat educa-
tional visits during this same time period; these visits were
related to COC pills and a repeat of the previous year’s ma-
terials. Thus, the treatment and control groups differed in
the content as well as the extent of program offerings: the
treatment group was offered participation in the DMPA
seminar and two DMPA educational visits, and the control
group was offered two repeat educational visits on COCs.
No information about DMPA was discussed during the
COC visits; thus, any detectable differences on knowledge,
attitudes, or practice related to DMPA can be attributed to
the influence of the DMPA program.
Data
A baseline survey was conducted in December 2011.
Survey questionnaires were mailed to all 267 providers,
and follow-up phone calls were made to providers who
did not respond to the mailed questionnaire. The ques-
tions asked for specific information relating to the pro-
viders’ knowledge of DMPA’s side effects, their attitudes
towards the method, and their clinical practices, such as
discussing DMPA with clients or prescribing it. The
response rate for the baseline survey was 73 % (195 pro-
viders), with no differential response rate between treat-
ment and control group [difference: −0.009 (S.E. 0.054)].
A face-to-face endline survey with providers was con-
ducted in January 2013. The endline survey collected in-
formation similar to the baseline: knowledge of DMPA’s
side effects, attitudes towards the method, confidence
about the method, and professional practices. It also col-
lected information such as years of experience, number
of patients seen, whether the provider has a dual (public
and private) practice, and the types of family planning
methods that the provider has prescribed in the last
year. Enumerators conducted in-office surveys, yielding
an endline response rate of 86 % (229 providers). There
was no statistically significant differential completion
rate across providers in the treatment and control
[difference: −0.018 (S.E. 0.043)]. Of those who were
interviewed at endline, 77 % had completed baseline
interviews.
Outcome measures
We are interested in four outcome measures: (1) pro-
viders’ knowledge of DMPA (for example, correct identi-
fication of side effects), represented as their Knowledge
Score; (2) their attitudes towards DMPA (including will-
ingness to recommend DMPA), represented as their
Attitude Score; (3) their self-perceived confidence level
(including confidence in discussing DMPA with clients),
represented as their Confidence Score; and (4) their re-
ported clinical practice (such as reported prescription or
discussion of DMPA with clients), represented as their
Practice Score. We compute scores for each of these
outcome measures as described below.
To measure knowledge and attitudes towards DMPA,
the survey respondents were asked to rate specific
knowledge and attitudes statements using a five-point
Likert scale, ranging from “strongly agree” to “strongly
disagree”. Examples of these statements are: “Use of
DMPA is positively associated with weight gain”; or, “I
would have no hesitation recommending DMPA to a
healthy woman.” We assign values ranging from −2 to +2
for each of the knowledge and attitude variables, where +2
denotes the most desirable response (e.g., “I strongly
agree” that I would have no hesitation recommending
DMPA to a healthy woman), and −2 denotes the least
desirable response. We create a Knowledge Score and
an Attitude Score for each provider using the simple
average of related variables. Following Kling et al. [22]
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we standardize the scores by subtracting the mean and
dividing by the standard deviation of the variable
among the EBM control group, such that the control
group’s mean is zero and its standard deviation is one.
To measure self-perceived confidence in DMPA, the
respondents were asked to provide answers to three
questions, using a ten-point scale. Examples of these
questions are: “How knowledgeable do you feel about
DMPA?” and “How comfortable do you feel prescribing
DMPA for your clients?” We form the simple average of
these three variables and create a Confidence Score that
we also standardize according to Kling et al. [22]. Confi-
dence outcomes were not collected at baseline.
To measure clinical practices related to DMPA, the re-
spondents were asked to report whether they have any
DMPA stock at their clinic, as well as the number of
times they discussed DMPA with clients or prescribed it
to their clients during the month prior to the survey.
We form z-scores of each of these three variables, com-
pute a Practice Score using the simple average, and then
similarly apply Kling et al. [22] to standardize the score
among the control group.
Appendix 1: Table 4 shows the components of each
score and the baseline means and standard deviations,
for the overall sample and by treatment and control.
Balance across treatment and control
Random assignment is most effective at establishing
comparable groups in large samples. Since ours is a
small sample, we checked the balance between treatment
and control groups. An examination of baseline charac-
teristics (Appendix 2: Table 5) confirms that random as-
signment resulted in a sample where, on average, there
are no statistically significant differences between treat-
ment and control groups. The balance between treat-
ment and control persists when the sample is restricted
to those who completed the endline survey (not shown).
Estimation strategy
We estimate the impact of the EBM DMPA program on
outcomes (Yi) as follows:
Y i ¼ α1 þ β1Ti þ X′γ þ ε1;i ð1Þ
T indicates that provider i was assigned to the treat-
ment group; β1 is the “intention to treat” (ITT) aspect of
the program’s estimated impact; and α1 is interpreted as
the control group’s regression-adjusted mean outcome.
When we regress the standardized outcome scores on T,
the resulting coefficient estimates are the mean effect
sizes and capture the average impact in terms of stand-
ard deviations of the outcome variables in the control.
The standardization facilitates comparison of impact
magnitudes across outcomes. The regression includes a
vector X of baseline covariates, which serves to reduce
noise attributable to random differences between the
groups. We impute missing baseline data with the mean
values and include dummy variables to the regression to
indicate imputation. Because of missing baseline data,
we show results both with and without the baseline
covariates.
To adjust for non-compliance, we also estimate the local
average treatment effects of actual participation in the
complete program (defined as attending the seminar and
receiving both of the educational visits). To do this, we in-
strument compliance with the EBM program (endogenous
variable) with the treatment assignment, using two-stage
least squares (2SLS) (Eq 2 and 3). This approximates the
“treatment on the treated” (TOT) effects (β2Þ, which are
expected to be larger than the ITT estimates.
Y i ¼ α2 þ β2 AC^TUALTi þ ε2;i ð2Þ
The first stage specification is given by:
ACTUAL Ti ¼ α3 þ β3Ti þ ε3;i ð3Þ
One potential threat to the validity of the specifica-
tions is the risk of spillovers from treatment to control;
however, this is unlikely for a number of reasons. First,
providers in the sample have their own private clinics
and do not share practices. Second, the surveys asked
whether providers had discussed medical evidence with
other providers or medical professionals, and we find no
statistically significant differences in frequency of discus-
sion between treatment and control groups.
Results
Figure 1 illustrates the results from separate regressions
of the ITT impact estimates of the EBM program, ex-
cluding baseline covariates. The black squares represent
the value of the coefficient on the treatment indicator
for each outcome variable. A positive coefficient indi-
cates that the program had a positive effect on outcomes
of interest, such as knowledge about DMPA or attitudes
towards the method. The figure also shows the 90 % confi-
dence intervals for each estimated coefficient. When the
confidence interval contains the value “0.00,” we are
unable to reject the null hypothesis that there was no sig-
nificant difference between the treatment and control.
Figure 1 shows no significant impact of the EBM pro-
gram on knowledge of DMPA’s side effects or on reported
clinical practices. The point estimates on the Knowledge
and Practice Scores are −0.02 and −0.01 respectively.
Figure 1 also shows that the Attitude and Confidence
Scores of providers in the treatment group are 0.14 and
0.21 standard deviations higher (respectively) compared to
the control group. While they suggest a move in the
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positive direction, these differences are not statistically sig-
nificant at traditional confidence levels.
Table 1 shows the ITT estimates when adding covari-
ates in the regressions and imputing missing baseline
data. The impact estimates on the treatment indicator
are slightly smaller in magnitude than the ones in the
parsimonious specification without covariates. Coeffi-
cients on the Attitude and Confidence Scores remain
positive (0.12 and 0.20 standard deviations in magnitude,
respectively), but are not statistically significant. Baseline
Attitude Scores and Practice Scores are strongly and
positively associated with key outcomes at endline. At
the same time, there is no relationship between the base-
line Knowledge Score and any outcome measure. Note
that we are powered to detect a difference of 0.33 stand-
ard deviations between the treatment and control groups
for our Knowledge, Attitudes, Confidence and Practice
Scores, using conservative assumptions (alpha 0.05, power
0.90, covariates explaining 0.25 of the variation).
Not all of the providers in the treatment group partici-
pated in the EBM seminar suggesting that the ITT
estimates above are a lower bound of the estimated
treatment effects. Approximately 45 % of the treatment
group providers invited to the EBM seminar participated
in the seminar (Table 2). Two control group providers
attended the seminar. Approximately 82 % of treatment
group providers received the first educational visit, while
79 % received the second educational visit; 76 % of the
treatment group providers received both visits. Accord-
ing to the program monitoring data, the provider’s busy
schedule was the most commonly cited reason for not
participating in the seminar or the educational visits.
Overall, 38 % of the treatment group received both edu-
cational visits and attended the seminar.
We show the TOT estimates in Fig. 2. The TOT esti-
mates are robust to various (partial) specifications of the
endogenous variable, such as participation in the sem-
inar and at least one educational visit rather than partici-
pation in the entire EBM program (not shown). While
larger than the ITT estimates in magnitude, the esti-
mates are not statistically significant.
We find some evidence of positive selection into the
seminar (Table 3). A comparison of baseline characteris-
tics between treatment group providers who did and did
not participate in the seminar shows that providers who
attended the seminar were, on average, significantly
more knowledgeable initially on DMPA than those who
did not attend: the average baseline Knowledge Score for
those who attended the seminar is 0.47 standard devia-
tions higher. Providers who attended the seminar are
also more likely to have more positive attitudes, though
these estimates are not statistically significant.
Discussion
This experimental study measures the impact of an EBM
program in Jordan aimed at addressing private provider
Fig. 1 Impact of EBM program on provider outcomes. The black squares denote the Intent-To-Treat coefficients without the baseline covariates;
The error bars denote the 90 % confidence level; Robust standard errors; For all scores, the control group mean is zero and the standard deviation
is one; The Y-axis is measured in terms of standard deviations of the outcome variable in the control group. N = 229 providers
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biases and misconceptions towards an unpopular contra-
ceptive method, DMPA.
We fail to detect an impact of the EBM program on
knowledge. However, we find suggestive evidence that
the program led to improved attitudes and confidence.
Although we hypothesized that the program would in-
crease knowledge which would then improve attitudes,
our results do not support this hypothesis. We also fail
to detect a change in provider-reported practices related
to DMPA—such as stocking DMPA, discussing DMPA
with patients, and prescribing DMPA. Strong consumer
bias against this method may also have made it difficult
for providers to discuss or recommend this method. Our
findings challenge the theory of behavior change that
underlies the EBM approach. It is unclear whether the
EBM approach as designed in this program is appropri-
ate or sufficient in bringing about changes in provider
behavior. In this context, EBM may need to be coupled
with additional consumer targeted measures that directly
address barriers against DMPA use.
Compared to participation rates at prior EBM semi-
nars conducted in Jordan for other family planning
methods (71 and 66 % for POP and COC, respectively),
attendance at the EBM DMPA seminar was very low at
45 %. While low attendance may be due to provider fa-
tigue, it may also be linked to the low demand and nega-
tive provider and consumer attitudes towards DMPA
compared to other family planning methods. We find
evidence of self-selection into the roundtable seminar:
treatment providers who attended the DMPA seminars
were on average better informed and more positive to-
ward DMPA than treatment providers who did not
attend. This finding underscores the importance of
conducting experimental evaluations to evaluate this
type of program. Analyses using cross-sectional data
are likely to be biased upward.
The results from this study are quite different from
the earlier pre-post EBM COC evaluation. That study
provided suggestive evidence that EBM increased pro-
vider knowledge about COC pills as well as their will-
ingness to prescribe COC pills to appropriate clients
and the number of times they discussed COC with
their patients. It is possible that EBM is a promising
approach for addressing medical topics where there is
less pre-existing provider bias. Alternatively, it is pos-
sible that the providers who participated in the EBM
COC seminars may have had high levels of knowledge
and fewer biases against COCs initially, given that
this study was a pre-post and did not have an experi-
mental design.
Given that we surveyed the majority of private providers
offering family planning services in Amman and Zarqa, our
results are generalizable in these particular areas. Our re-
sults, however, may not be applicable to EBM programs im-
plemented elsewhere, or those related to other family
planning methods or topics.
Our study has some important limitations. The relatively
small sample size limits our ability to detect small to
medium effects with statistical precision. The questions
Table 2 Compliance with the EBM program (percentages)
Treatment Control
Providers who attended the EBM seminar 0.45 0.01
Providers who received first educational visit
on DMPA
0.82 0
Providers who received second educational
visit on DMPA
0.79 0
Providers who received both educational
visits on DMPA
0.76 0
Providers who received at least one educational
visit on DMPA
0.85 0
Providers who attended the seminar AND
received both educational visits on DMPA
0.38 0
N = 135 for treatment; N = 132 for control
Table 1 ITT impact of EBM program on outcomes (including
baseline covariates)











Treatment −0.03 0.12 0.20 0.04
[0.13] [0.13] [0.14] [0.12]
Female 0.67*** −0.10 0.17 0.24**
[0.13] [0.13] [0.16] [0.11]
Amman 0.05 0.04 0.24 0.23
[0.15] [0.14] [0.17] [0.15]
Number of patients −0.000 0.000 0.001 0.003***
[0.001] [0.001] [0.001] [0.001]
Baseline knowledge
score
0.07 0.02 0.03 0.15**
[0.08] [0.07] [0.08] [0.07]
Baseline attitude
score
0.13* 0.27*** 0.27*** 0.08
[0.08] [0.09] [0.08] [0.06]
Baseline practice
score
0.06 −0.02 0.10** 0.34***
[0.07] [0.05] [0.05] [0.10]
Constant -0.38* 0.04 −0.36 -0.61***
[0.20] [0.2] [0.24] [0.20]
N 229 229 229 229
R-squared 0.20 0.14 0.18 0.33
Each column shows results from a separate OLS regression. Missing vales at
baseline are imputed. All regressions include dummies for missing variables
(coefficients not shown). ***Significant at the 1 percent level. **Significant at
the 5 percent level. *Significant at the 10 percent level
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asked in the survey may be insufficient to comprehensively
gauge health provider attitudes. A more detailed set of
questions would have been preferable; however the ques-
tionnaires were designed to be concise to minimize bur-
den on the respondents and remain within budget. In
addition, reported practices can differ substantially from
actual practices [23, 24]. It would have been ideal to meas-
ure provider practices through the use of a mystery client
survey or client exit surveys. However, these options were
not socially acceptable in this particular setting, and risked
creating disruptions in the relationship between providers
and program staff. Finally, with only one seminar and two
follow-up educational visits over the course of six months,
the dosage of this intervention may be too low to alter at-
titudes and clinical behaviors. We are unable to determine
with our study design whether a more intensive approach
would have been more effective.
Conclusions
Our study does not find evidence that EBM is effective
as a stand-alone program targeting a highly unpopular
family planning method in a middle-income country.
The study suggests that non-randomized methods are in-
adequate for measuring the impact of programs with this
type of self-selection. If EBM is to be used widely in con-
junction with family planning methods in low- and middle-
income countries, it should be rigorously evaluated again
with a different family planning method and/or in conjunc-
tion with a demand-side campaign, possibly in different set-
tings. An evaluation would also benefit from a mixed
method approach as qualitative data could help better
contextualize and explain findings. As provider misconcep-
tions and biases towards family planning methods continue
to create barriers to access among women in low- and
middle-income countries, the family planning community
needs to continue to implement and test interventions that
address this issue.
Fig. 2 Adjusted impact of EBM program on provider outcomes (TOT estimates). The black squares denote Treatment on the Treated coefficients
from Equation (2); The error bars denote the 90 % confidence level; Robust standard errors. For all scores, the control group mean is zero and
standard deviation is one. N = 229 providers










Baseline Knowledge Score(a) 0.47 0.00 0.47** 0.21
Baseline Attitude Score(a) 0.21 0.00 0.21 0.20
Baseline Practice Score(a) 0.10 0.00 0.10 0.21
Female 0.77 0.61 0.16** 0.08
Amman 0.84 0.78 0.05 0.07
Years of family planning experience 17.0 17.3 −0.29 1.57
Sample range(b) 46–61 50–74
(a)For all scores, the group of providers who did not attend the seminar has a
mean of zero and a standard deviation of one
(b)The sample size ranges from 46 to 61 in column (A) and from 50 to 74 for
column (B) because of missing observations
**Significant at the 5 percent level.
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Appendix 1
Appendix 2
Table 4 Outcome measures at baseline
Overall sample Treatment Control
Mean S.D. N Mean S.D. N Mean S.D. N
Knowledge of DMPAa
Women are at a higher risk of ectopic pregnancy if they use DMPA long term 0.77 0.93 192 0.72 0.96 96 0.81 0.90 96
DMPA use is associated with an increased incidence of breast cancer 0.85 0.97 193 0.85 1.03 96 0.85 0.92 97
Women who use DMPA are less likely to suffer from anemia 0.64 0.98 193 0.77 0.92 96 0.52 1.02 97
From time to time, a woman using DMPA should give her body a rest −0.18 1.26 192 0.06 1.28 96 −0.42 1.19 96
Use of DMPA is positively associated with weight gain 0.09 1.01 192 0.04 1.00 96 0.15 1.02 96
DMPA use is safe for most healthy women 1.13 0.77 191 1.16 0.87 95 1.10 0.66 96
Women who use DMPA are more likely to experience amenorrheab — — — — — — — — —
Women who use DMPA are more likely to experience spottingb — — — — — — — — —
Attitudes towards DMPAa
For some women, amenorrhea can be a benefit 0.63 1.10 191 0.79 1.04 95 0.48 1.13 96
I should not prescribe DMPA to nulliparous women who wish to delay childbirth −0.65 1.24 191 −0.57 1.28 94 −0.72 1.21 97
If women in Jordan had more information about DMPA, more women might accept its use 0.85 1.05 182 0.76 1.11 88 0.93 0.99 94
I would have no hesitations to recommend DMPA to a healthy woman who wanted to
use this method
0.95 1.04 192 0.98 0.99 96 0.93 1.09 96
Perceived confidence towards DMPAb
How knowledgeable do you feel about DMPA? — — — — — — — — —
How confident do you feel discussing DMPA with clients? — — — — — — — — —
How comfortable do you feel prescribing DMPA as a contraceptive method to your clients? — — — — — — — — —
Baseline Practices
Availability of DMPA stock at clinic (binary) 0.22 0.41 183 0.20 0.40 94 0.24 0.43 89
Average # times discussed DMPA with clients in past month 5.41 7.57 187 5.10 5.76 94 5.73 9.06 93
Average # times prescribed DMPA to clients in past month 2.19 3.62 184 2.00 3.49 91 2.38 3.75 93
aValues range from −2 to +2, where +2 denotes the most knowledgeable or desirable response and −2 denotes the least knowledgeable or desirable response
bThese outcomes were not collected at baseline
Table 5 Characteristics of providers
Treatment Control Difference (T-C)
Mean SE
Female(a) 0.68 0.69 −0.01 0.06
Average years of clinical experience 24.6 24.8 −0.20 1.07
Average years of clinical experience in family planning 17.1 17.6 −0.50 1.19
Providers with dual practice (in public and private sectors) 0.14 0.09 0.05 0.04
Method provision/prescription in clinic
Copper intrauterine contraceptive device (IUCD) 0.93 0.95 −0.02 0.03
Hormonal intrauterine system (Mirena®) 0.67 0.62 0.06 0.06
Implant (Implanon®) 0.32 0.29 0.03 0.06
Combined oral contraceptive (COC) pill 0.97 0.99 −0.02 0.02
Progestin-only pill 0.94 0.95 −0.01 0.03
Vaginal ring (NuvaRing®) 0.41 0.39 0.02 0.06
Condom 0.94 0.97 −0.03 0.03
Female sterilization (e.g. bilateral tubal ligation) 0.57 0.56 0.01 0.07
Male sterilization (vasectomy) 0.08 0.09 −0.01 0.04
Baseline Knowledge Score (standardized)(b) 0.18 0.00 0.18 0.15
Baseline Attitude Score (standardized)(b) 0.15 0.00 0.15 0.15
Baseline Practice Score (standardized)(b) −0.15 0.00 −0.15 0.12
Baseline Availability of DMPA stock at clinic(b) 0.20 0.24 −0.03 0.06
Baseline Average # times discussed DMPA with clients in past month(b) 5.1 5.7 −0.64 1.10
Baseline Average # times prescribed DMPA in past month(b) 2.0 2.4 −0.38 0.53
N 117 112
(a) N = 137 for the control group; N = 135 for the treatment group
(b) The sample size ranges from 89 to 96 for the control group and from 91 to 97 for the treatment group because of missing observations
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COC: Combined Oral Contraception; CONSORT: Consolidated Standards of
Reporting Trials; DMPA: Depot Medroxy Progesterone Acetate;
EBM: Evidence-Based Medicine; ITT: Intention to treat; POP: Progesterone
Only Pills; SHOPS: Strengthening Health Outcomes through the Private
Sector Project; TOT: Treatment on the treated; USAID: United States Agency
for International Development.
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